At the news
? NEUTRALIMPACT 4/10 COURT-RULING filed May 26, 2026 at 20:00 ET
The Delaware Court of Chancery ruled that Syntimmune (acquired by AstraZeneca/Alexion) breached its merger agreement representation regarding cGMP compliance of drug substance and drug product lots. The court awarded AstraZeneca approximately $11.1 million in indemnification for replacement manufacturing costs, but denied its claim for ~$375 million in benefit-of-the-bargain damages as speculative. The ruling is a modest financial win for AZN but represents a small fraction of the $580B market cap.
- Court found Syntimmune breached Section 4.13(a) of the merger agreement by failing to manufacture drug lots in compliance with cGMP standards
- AstraZeneca awarded $11,115,556.33 in indemnification for replacement drug substance and drug product costs
- Court denied AstraZeneca's claim for ~$375 million in benefit-of-the-bargain damages as entirely speculative and unsupported by evidence
- The ruling resolves a post-acquisition dispute over contaminated drug materials that caused clinical trial delays
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access